Indication
Lymphoma, B-Cell, Mediastinal
1 clinical trial
4 products
3 drugs
Clinical trial
A Phase II Study of Nivolumab in Combination With DA-REPOCH Followed by Short Course Nivolumab Consolidation in Patients With Aggressive B-Cell Non-Hodgkin's LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-07-31
Drug
cyclophosphamideProduct
DoxorubicinProduct
EtoposideProduct
NivolumabProduct
PrednisoneDrug
VarlilumabDrug
Vincristine